This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adinoff, A. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Adinoff, A. D.

PEDIATRICS Vol. 104 No. 2 Supplement August 1999, pp. 392

Leukotriene Antagonist Therapy
Montelukast, A Once-Daily Leukotriene Receptor Antagonist, In theTreatment of Chronic Asthma: A Multicenter, Randomized, Double-BlindTrial

Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB Arch Intern Med. 1998; 158:1213-1220 [Medline]

The first 20% of the full text of this article appears below.

Purpose of the Study To determine the clinical effect of oral montelukast sodium, a leukotriene receptor antagonist, in asthmatic patients aged 15 years or more.

Study Population Fifty clinical centers randomly allocated 681 patients with chronic, stable asthma to receive placebo or montelukast after demonstrating a forced expiratory volume in 1 second (FEV1) 50% to 85% of the predicted value, at least a 15% improvement FEV1 (absolute value) after inhaled beta -agonist administration, a minimal predefined level of . . . [Full Text of this Article]